| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 73, 931-935, Copyright © 1991 by Endocrine Society
ARTICLES |
AW Meikle, JC Cardoso de Sousa, JH Ward, M Woodward and WE Samlowski
Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City 84132.
We have investigated the effect of high dose iv bolus interleukin-2 (IL- 2) therapy on sex hormone and adrenal steroid concentrations in six men treated for metastatic renal cell carcinoma or malignant melanoma. Blood concentrations of testosterone, 17 beta-estradiol, LH, FSH, cortisol, dehydroepiandrosterone (DHEA), and DHEA sulfate (DHEA-S) were measured before and after a 5-day course of IL-2 therapy. Cortisol levels rose and DHEA-S decreased insignificantly. DHEA declined, reaching a nadir (P less than 0.001) on day 6, and testosterone decreased significantly on day 2 and reached a nadir on day 6 (P less than 0.0001). Concentrations of both steroids then gradually rose. Estradiol rose on day 4 (P less than 0.001) and then declined. Neither LH nor FSH was affected significantly, although there was a rise in the mean level of LH after IL-2 therapy. Our results suggest that high dose IL-2 therapy in men affects both adrenal and testicular androgen production without inhibiting pituitary trophic hormone secretion. These effects of IL-2 on plasma sex steroids may be the result of cytokines stimulated by IL-2 therapy, rather than direct responses to IL-2.
This article has been cited by other articles:
![]() |
M. P. Purdue, L. C. Sakoda, B. I. Graubard, R. Welch, S. J. Chanock, I. A. Sesterhenn, M. V. Rubertone, R. L. Erickson, and K. A. McGlynn A Case-Control Investigation of Immune Function Gene Polymorphisms and Risk of Testicular Germ Cell Tumors Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 77 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Weidinger, R. Hein, J. Ring, and F. M. Kohn Endocrinologic Changes in Male Patients With Melanoma During Interferon Alfa-2b Therapy Arch Dermatol, April 1, 2002; 138(4): 541 - 542. [Full Text] [PDF] |
||||
![]() |
J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel The Endocrine Effects of Nonhormonal Antineoplastic Therapy Endocr. Rev., April 1, 1998; 19(2): 144 - 172. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |